Fábio Moura

Dr. Fábio Moura


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2020 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
JSJoão Eduardo Nunes Salles
João Eduardo Nunes Salles
JSJose Silva-Nunes
Jose Silva-Nunes
HPHermelinda Cordeiro Pedrosa
Hermelinda Cordeiro Pedrosa
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
CLCristiane Bauermann Leitão
Cristiane Bauermann Leitão
Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM.Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria.Results and conclusions: In non-pregnant adults, the recommended HbA1ctarget is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1cis 6.5–7.5%. When HbA1cis 7.5–9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1cremains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction (< 40%) and glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2, metformin plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30–60 mL/min/1.73 m2or eGFR 30–90 mL/min/1.73 m2with albuminuria > 30 mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM.

2 December 2024 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RMRodrigo O. Moreira
Rodrigo O. Moreira
CVCynthia M. Valerio
Cynthia M. Valerio
AHAlexandre Hohl
Alexandre Hohl
CMCristiane Moulin
Cristiane Moulin
FMFábio Moura
Fábio Moura
BHBruno Halpern
Bruno Halpern
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), [...] ABSTRACT Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM),

1 September 2015 in Nutrients
Verified
Journal Article
Open access
PDF file
FMFábio Moura
Fábio Moura
JSJoão Salles
João Salles
OHOsama Hamdy
Osama Hamdy
WCWalmir Coutinho
Walmir Coutinho
DBDeise Regina Baptista
Deise Regina Baptista
JMJeffrey I mechanick
Jeffrey I mechanick
The prevalence of obesity, pre-diabetes, and type 2 diabetes (T2D) is increasing worldwide, especially in the developing nations of South America. Brazil has experienced an exponential increase in the prevalence of these chronic non-communicable diseases. The rising prevalence is probably due to changing eating patterns, sedentary living, and a progressive aging of the population. These trends and their underlying causes carry untoward consequences for all Brazilians and the future of Brazilian public health and the healthcare system. Lifestyle changes that include healthy eating (nutrition therapy) and regular physical activity (structured exercise) represent efficient inexpensive measures to prevent and/or treat the aforementioned disorders and are recommended for all afflicted patients. Regrettably, the implementation of lifestyle changes is fraught with clinical and personal challenges in real life. The transcultural Diabetes Nutrition Algorithm (tDNA) is a therapeutic tool intended to foster implementation of lifestyle recommendations and to improve disease-related outcomes in common clinical settings. It is evidence-based and amenable to cultural adaptation. The Brazilian Diabetes Association, Society of Cardiology and Ministry of Health guidelines for nutrition therapy and physical exercise were considered for the Brazilian adaptation. The resultant tDNA-Brazil and its underlying recommendations are presented and explained.

6 October 2025 in Acta Medica (Hradec Kralove, Czech Republic)
Verified
Journal Article
Open access
PDF file
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
VSVanessa de Oliveira E Silva
Vanessa de Oliveira E Silva
ÍJÍtalo Caio Lopes Jucá
Ítalo Caio Lopes Jucá
JTJoão Victor Gonçalves Dos Santos Torres
João Victor Gonçalves Dos Santos Torres
MTMaria Roseneide Dos Santos Torres
Maria Roseneide Dos Santos Torres
FBFrancisco Bandeira
Francisco Bandeira
Myosteatosis refers to the infiltration of fat into skeletal muscle tissue, being influenced by factors such as advanced age and overweight, which increase the inability of adipocytes to store lipids. This condition not only alters the structure of the muscle but is also associated with endocrinological imbalances such as insulin resistance (IR) and hyperinsulinemia, increasing the risk of developing type 2 diabetes mellitus (T2DM) and cardiovascular diseases. Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are effective methods for measuring myosteatosis, identifying areas of fat accumulation that may indicate specific regional patterns. This review aimed to evaluate the main evidence that associates myosteatosis with T2DM, compiling the epidemiological data already available on the subject and the main gaps in the literature. Ten observational studies were selected, from different regions of the world, which showed a relationship between myosteatosis and a higher incidence of T2DM, as well as IR, worse glycemic status, increased inflammatory mediators and a tendency to coronary artery disease. In conclusion, myosteatosis and T2DM are conditions with a relevant relationship and that have significant implications for public health, requiring greater standardization of myosteatosis assessment methods and interventional studies that address potential therapeutic strategies for this condition.

22 June 2023 in Revista de Ciências Médicas e Biológicas
Verified
Journal Article
Open access
PDF file
LOLucian Batista de Oliveira
Lucian Batista de Oliveira
BBBeatriz Pontes Barreto
Beatriz Pontes Barreto
ACAlice Rodrigues Pimentel Correia
Alice Rodrigues Pimentel Correia
VLVinícius Belfort Leão
Vinícius Belfort Leão
FMFábio Moura
Fábio Moura
FBFrancisco Bandeira
Francisco Bandeira
Introdução: a insuficiência cardíaca (IC) e a sarcopenia são condições prevalentes e inter-relacionadas, figurando como importantes causas de limitações funcionais. Objetivo: avaliar critérios de sarcopenia, e suas relações com parâmetros cardiometabólicos, em pacientes de 40 a 64 anos hospitalizados por IC. Metodologia: estudo de corte transversal com caráter analítico envolvendo indivíduos com IC confirmada. A massa muscular apendicular (MMA) foi avaliada através da absorciometria por raios-X de dupla energia (DXA), considerando-se baixa MMA mulheres com MMA/altura² <5,5 kg/m² ou MMA/índice de massa corporal (IMC) <0,512 e homens com MMA/altura² <7,0 kg/m² ou MMA/IMC <0,789. Baixa força de preensão manual (FPM) foi considerada quando <16 kg em mulheres e <27 kg em homens. Resultados: avaliou-se 109 pacientes (50,5% mulheres), com mediana de idade de 58 anos. Constatou-se baixa MMA em 41,3% e baixa FPM em 64,2%, não havendo correlação significativa entre FPM e MMA em nenhum dos gêneros. Baixa MMA se associou ao gênero masculino (68,9% versus 35,9%; p=0,001), a maiores idades (60,0 [53,0-63,0] versus 57,0 [51,3-60,0] anos; p=0,039) e maiores níveis séricos de paratormônio (48,0 [30,5-94,4] versus 29,9 [23,0-54,1] pg/mL; p=0,009). Baixa FPM se associou a maior sintomatologia cardíaca (75,7% com baixa FPM tinham classificação funcional da New York Heart Association III-IV, versus 51,3% daqueles com FPM normal; p=0,009). Conclusões: há uma relevante prevalência de sarcopenia em pacientes de 40 a 64 anos hospitalizados por IC, observando-se maior frequência de baixa MMA nos homens, associação entre baixa FPM e sintomatologia cardíaca, e maiores níveis de paratormônio naqueles com perda muscular.